Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials

The Lancet

Volumn 385, Issue 9987, 2015, Pages 2606-2615

  Sax, Paul E ^a   Wohl, David ^b   Yin, Michael T ^c   Post, Frank ^d   DeJesus, Edwin ^e   Saag, Michael ^f   Pozniak, Anton ^g   Thompson, Melanie ^h   Podzamczer, Daniel ⁱ   Molina, Jean Michel ^j   Oka, Shinichi ^k   Koenig, Ellen ^l   Trottier, Benoit ^m   Andrade Villanueva, Jaime ⁿ   Crofoot, Gordon ^o   Custodio, Joseph M ^p   Plummer, Andrew ^p   Zhong, Lijie ^p   Cao, Huyen ^p   Martin, Hal ^p   Callebaut, Christian ^p   Cheng, Andrew K ^p   Fordyce, Marshall W ^p   McCallister, Scott ^p   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c College of Physicians and Surg ^*  (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ORLANDO IMMUNOLOGY CENTER   (United States)

^f University of Alabama at Birmingham   (United States)

^g CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^h AIDS Research Consortium of Atlanta   (United States)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j SAINT LOUIS HOSPITAL   (France)

^k NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^l Instituto Dominicano de Estudios Virologicos   (Dominican Republic)

^m Clinique Medicale l'Actuale in Montreal   (Canada)

ⁿ UNIVERSITY OF GUADALAJARA   (Mexico)

^o Gordon Crofoot Research   (United States)

^p GILEAD SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COBICISTAT; CREATININE; ELVITEGRAVIR; EMTRICITABINE; PLACEBO; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBAMIC ACID DERIVATIVE; DEOXYCYTIDINE; DRUG COMBINATION; GS-7340; PHOSPHONIC ACID DERIVATIVE; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INSOMNIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANALOGS AND DERIVATIVES; BREATHING DISORDER; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; HEADACHE; HIV INFECTIONS; KIDNEY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; ARTHRALGIA; BONE DENSITY; CARBAMATES; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEADACHE; HIV INFECTIONS; HUMANS; KIDNEY; MALE; NAUSEA; ORGANOPHOSPHONATES; QUINOLONES; RESPIRATION DISORDERS; SLEEP INITIATION AND MAINTENANCE DISORDERS; THIAZOLES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84937215233     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60616-X     Document Type: Article

References (27)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2011 Department of Health and Human Services 1 166 http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed Feb 2, 2015).
2. SK Gupta Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system AIDS Patient Care STDS 22 2008 99 103
3. A Mocroft, O Kirk, P Reiss the EuroSIDA Study Group Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients AIDS 24 2010 1667 1678
4. P Morlat, A Vivot, MA Vandenhende the Groupe D'epidémiologie Clinique du Sida en Aquitaine (Gecsa) Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012 PLoS One 8 2013 e66223
5. GA McComsey, D Kitch, ES Daar et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202 J Infect Dis 203 2011 1791 1801
6. R Bedimo, NM Maalouf, S Zhang, H Drechsler, P Tebas Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents AIDS 26 2012 825 831
7. KK Van Rompay, L Durand-Gasselin, LL Brignolo et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects Antimicrob Agents Chemother 52 2008 3144 3160
8. CA Fux, M Simcock, M Wolbers the Swiss HIV Cohort Study Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study Antivir Ther 12 2007 1165 1173
9. M Goicoechea, S Liu, B Best the California Collaborative Treatment Group 578 Team Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy J Infect Dis 197 2008 102 108
10. JJ Kiser, ML Carten, CL Aquilante et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients Clin Pharmacol Ther 83 2008 265 272
11. PJ Ruane, E DeJesus, D Berger et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults J Acquir Immune Defic Syndr 63 2013 449 455
12. PE Sax, A Zolopa, I Brar et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study J Acquir Immune Defic Syndr 67 2014 52 58
13. Guidance for Industry: Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Dtrugs for Treatment June 2013 U.S.Department of Health and Human Services Food and Drug Administation, Center for Drug Evaluatin and Research http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm355128.pdf (accessed Feb 2, 2015).
14. GG Koch, GJ Carr, IA Amara et al. Categorical data analysis DA Berry Statistical methodology in the pharmaceutical sciences 1989 Marcel Dekker, Inc. New York 41 21
15. BL Wiens, A Dmitrienko The fallback procedure for evaluating a single family of hypotheses J Biopharm Stat 15 2005 929 942
16. C Lewden, G Chene, P Morlat the Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO8 APROCO-COPILOTE Study Group the Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO3 AQUITAINE Study Group HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population J Acquir Immune Defic Syndr 46 2007 72 77
17. RD Cooper, N Wiebe, N Smith, P Keiser, S Naicker, M Tonelli Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients Clin Infect Dis 51 2010 496 505
18. R Scherzer, M Estrella, Y Li et al. Association of tenofovir exposure with kidney disease risk in HIV infection AIDS 26 2012 867 875
19. TT Brown, RB Qaqish Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review AIDS 20 2006 2165 2174
20. B Grund, G Peng, CL Gibert the INSIGHT SMART Body Composition Substudy Group Continuous antiretroviral therapy decreases bone mineral density AIDS 23 2009 1519 1529
21. PM Grant, D Kitch, GA McComsey et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation Clin Infect Dis 57 2013 1483 1488
22. H-J Stellbrink, C Orkin, JR Arribas the ASSERT Study Group Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study Clin Infect Dis 51 2010 963 972
23. L Mateo, S Holgado, ML Marinoso et al. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients Clin Rheumatol 2014 10.1007/s10067-014-2627-x published online May 3.
24. J Reynes, R Trinh, F Pulido et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study AIDS Res Hum Retroviruses 29 2013 256 265
25. RJ Bedimo, H Drechsler, M Jain et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health PLoS One 9 2014 e106221 10.1371/journal.pone.0106221
26. JA Shepherd, Y Lu A generalized least significant change for individuals measured on different DXA systems J Clin Densitom 10 2007 249 258
27. M Tungsiripat, D Kitch, MJ Glesby et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206 AIDS 24 2010 1781 1784